- Open
- 87.44
- High
- 88.00
- Low
- 87.00
- Close
- 87.00
- Change
- -0.80 (-0.91%)
- Volume
- 121,510
⌘K
| 16 Mar 2026 | 14:16:22 | Holding(s) in Company |
| 3 Mar 2026 | 11:00:01 | Results of General Meeting and Board Changes |
| 3 Mar 2026 | 09:30:00 | Quell Clinical Updates |
| 12 Feb 2026 | 12:00:01 | Publication of Circular |
| 5 Feb 2026 | 07:00:04 | Third Quarter Update |
| 2 Jul 2025 | Annual Report and Accounts 2025 | |
| 4 Jul 2024 | Annual Report and Accounts 2024 | |
| 28 Jun 2023 | Annual Report and Accounts 2023 |
Syncona is dedicated to investing in companies that aim to improve and prolong human life. Our focus is on creating and developing businesses that provide innovative therapies to address significant medical challenges and benefit patients.
Lord Thurlow has interests in this issuer
| 16 Mar 2026 | 14:16:22 | Holding(s) in Company |
| 3 Mar 2026 | 11:00:01 | Results of General Meeting and Board Changes |
| 3 Mar 2026 | 09:30:00 | Quell Clinical Updates |
| 12 Feb 2026 | 12:00:01 | Publication of Circular |
| 5 Feb 2026 | 07:00:04 | Third Quarter Update |
| 2 Jul 2025 | Annual Report and Accounts 2025 | |
| 4 Jul 2024 | Annual Report and Accounts 2024 | |
| 28 Jun 2023 | Annual Report and Accounts 2023 |
Syncona is dedicated to investing in companies that aim to improve and prolong human life. Our focus is on creating and developing businesses that provide innovative therapies to address significant medical challenges and benefit patients.
Lord Thurlow has interests in this issuer
